Most recently, a randomized trial according to the application of biomarker-stratified interventional design in IBD (62) reported the failure to demonstrate the clinical utility of a CD8 T-cell transcriptional signature which was previously represented to be associated with the requirement for treatment escalation in IBD (63) but was challenged by later study (64). The gene discussed is CD8A; the disease is inflammatory bowel disease.